Aliases & Classifications for Excessive Tearing

MalaCards integrated aliases for Excessive Tearing:

Name: Excessive Tearing 12 15 73
Lacrimal Apparatus Diseases 44 73
Excessive Tear Production 12
Watering Eye 12
Epiphora 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13757
ICD10 33 H04.2 H04.20
ICD9CM 35 375.2 375.20
MeSH 44 D007766
NCIt 50 C50552
SNOMED-CT 68 49393005

Summaries for Excessive Tearing

MalaCards based summary : Excessive Tearing, also known as lacrimal apparatus diseases, is related to dacryocystitis and early-onset glaucoma, and has symptoms including visual disturbance, eye manifestations and discharge from eye. An important gene associated with Excessive Tearing is DCXR (Dicarbonyl And L-Xylulose Reductase), and among its related pathways/superpathways is G-protein signaling_Rap2B regulation pathway. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include eye, breast and bone, and related phenotype is vision/eye.

Related Diseases for Excessive Tearing

Diseases related to Excessive Tearing via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 dacryocystitis 32.2 DCXR OPTN
2 early-onset glaucoma 31.4 CYP1B1 MYOC
3 lacrimal apparatus disease 12.4
4 epiphora due to insufficient drainage 12.1
5 epiphora due to excess lacrimation 12.1
6 bell's palsy 11.2
7 aplasia of lacrimal and salivary glands 11.2
8 epithelial recurrent erosion dystrophy 11.0
9 dyskeratosis congenita, autosomal dominant 1 11.0
10 rapp-hodgkin syndrome 11.0
11 dyskeratosis congenita, autosomal dominant 3 11.0
12 acute canaliculitis 11.0
13 corneal dystrophy, epithelial basement membrane 11.0
14 tyrosinemia, type ii 11.0
15 cluster headache 11.0
16 acute inflammation of lacrimal passage 10.1 DCXR OPTN
17 lacrimal duct obstruction 10.1 DCXR OPTN
18 oncocytoma 10.1
19 acrofrontofacionasal dysostosis 10.0 CYP1B1 OPTN
20 megalocornea 10.0 LTBP2 OPTN
21 glaucoma 3, primary infantile, b 10.0 CYP1B1 LTBP2
22 axenfeld-rieger syndrome 10.0 CYP1B1 OPTN
23 torticollis 10.0
24 lymphoma 10.0
25 ptosis 10.0
26 acute dacryocystitis 10.0
27 facial paralysis 10.0
28 ectropion 10.0
29 pleomorphic adenoma 10.0
30 adenoma 10.0
31 dacryocystocele 10.0
32 aniridia 1 10.0 CYP1B1 OPTN
33 low tension glaucoma 10.0 MYOC OPTN
34 breast cancer 9.9
35 ocular hypertension 9.9 MYOC OPTN
36 hydrophthalmos 9.9 CYP1B1 LTBP2 OPTN
37 optic nerve disease 9.9 MYOC OPTN
38 glaucoma 1, open angle, a 9.8 CYP1B1 MYOC OPTN
39 coloboma of macula 9.8 CYP1B1 OPTN
40 juvenile glaucoma 9.8 CYP1B1 MYOC OPTN
41 primary angle-closure glaucoma 9.8 CYP1B1 MYOC OPTN
42 glaucoma, primary open angle 9.8 CYP1B1 MYOC OPTN
43 facioscapulohumeral muscular dystrophy 1 9.8
44 lymphoma, hodgkin, classic 9.8
45 myxedema 9.8
46 dyskeratosis congenita, x-linked 9.8
47 lymphoma, non-hodgkin, familial 9.8
48 aneurysmal bone cysts 9.8
49 b-cell lymphomas 9.8
50 marginal zone b-cell lymphoma 9.8

Graphical network of the top 20 diseases related to Excessive Tearing:



Diseases related to Excessive Tearing

Symptoms & Phenotypes for Excessive Tearing

UMLS symptoms related to Excessive Tearing:


visual disturbance, eye manifestations, discharge from eye, dacryops, watery eyes

MGI Mouse Phenotypes related to Excessive Tearing:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.02 CYP1B1 FGF10 GNAT2 LTBP2 MYOC

Drugs & Therapeutics for Excessive Tearing

Drugs for Excessive Tearing (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 298)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
3
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2 90566-53-3 62924
4
Fexofenadine Approved, Investigational Phase 4,Phase 3 83799-24-0 3348
5
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6, 75614-87-8 774
6
Loratadine Approved, Investigational Phase 4,Phase 3 79794-75-5 3957
7
Loteprednol Approved, Experimental Phase 4 82034-46-6, 129260-79-3 9865442 444025
8
Cetirizine Approved Phase 4,Phase 2,Phase 3 83881-51-0 2678
9
Montelukast Approved Phase 4,Phase 3,Phase 2 158966-92-8 5281040
10
Levocetirizine Approved Phase 4,Phase 2 130018-77-8 1549000
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Remifentanil Approved Phase 4 132875-61-7 60815
14
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
15
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
16
Ketorolac Approved Phase 4,Phase 2,Phase 3 66635-83-4, 74103-06-3 3826
17
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
18
Alcaftadine Approved Phase 4 147084-10-4 19371515
19
Azelastine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58581-89-8 2267
20
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
21
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
22
Polyestradiol phosphate Approved Phase 4 28014-46-2
23
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
24 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
25
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
26
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
27
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2 242138-07-4
28
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
29
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
30
Rhein Experimental Phase 4 478-43-3 10168
31
Bromfenac Approved July 1997 Phase 4,Phase 3 91714-94-2 60726
32 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
39 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
43 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Platelet Aggregation Inhibitors Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 271)
# Name Status NCT ID Phase Drugs
1 The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora Completed NCT01010659 Phase 4
2 Intranasal Steroids and the Nasal Ocular Response Completed NCT00473915 Phase 4 fluticasone furoate
3 Clinical Assessment of the Total Vaginal Mesh Technique for Treatment of Genital Prolapse Completed NCT00196495 Phase 4
4 A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712) Completed NCT01469234 Phase 4 loratadine;fexofenadine;placebo to loratadine;placebo to fexofenadine
5 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
6 Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms Completed NCT01007253 Phase 4 PL nasal spray;fluticasone furoate (FF);PL eye drops;olopatadine (OLO)
7 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
8 Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects Completed NCT00295022 Phase 4 Placebo;Montelukast;Levocetirizine
9 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
10 A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis Completed NCT00653224 Phase 4 levocetirizine dihydrochloride;placebo
11 Recovery After Sugammadex(Propofol vs Sevoflurane) Completed NCT01579851 Phase 4 Sugammadex
12 A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis Completed NCT00609674 Phase 4 Fluticasone furoate nasal spray;Placebo
13 Pain Management in Corneal Collagen Crosslinking for Keratoconus Completed NCT02867176 Phase 4 Gabapentin;Ketorolac
14 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
15 Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid Completed NCT00845195 Phase 4 Olopatadine HCl Nasal Spray, 0.6%;Azelastine HCl Nasal Spray, 0.1%
16 Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial Completed NCT00691665 Phase 4 Olopatadine HCL Nasal Spray, 0.6%;Fluticasone Propionate Nasal Spray, 50 mcg
17 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
18 The Role of Gabapentin in Postoperative Pain and Epithelialization After Photorefractive Keratectomy Completed NCT01177514 Phase 4 Gabapentin;Sugar pill
19 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
20 A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis Completed NCT01916226 Phase 4 FPNS;FPNS Placebo;Cetirizine;Cetirizine Placebo
21 A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber Completed NCT00848965 Phase 4 Fluticasone propionate;Placebo
22 Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine Completed NCT00502775 Phase 4 fluticasone furoate, fexofenadine
23 A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed NCT00495612 Phase 4 Omalizumab;Placebo
24 Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine Completed NCT00435461 Phase 4 Fluticasone furoate and fexofenadine
25 VISmodegib for ORbital and Periocular Basal Cell Carcinoma Recruiting NCT02436408 Phase 4 Vismodegib
26 Bromfenac Versus Dexamethasone After Cataract Surgery Active, not recruiting NCT03317847 Phase 4 Bromfenac 0.09 % Ophthalmic Solution;Dexamethasone 0.1% ophthalmic suspension
27 Non-specific Effects of Rabies Vaccine Enrolling by invitation NCT03656198 Phase 4 Sterile Water Injection
28 Evaluation of Cortisone Treatment in Children With Acute Facial Nerve Palsy Not yet recruiting NCT03781700 Phase 4 Prednisolone;Placebo Oral Tablet
29 The Effect of the Modified Perineal Protection Device During Delivery Unknown status NCT02013752 Phase 2, Phase 3
30 Mgt of Chronic Subdural Hematoma Using Dexamethasone Unknown status NCT02938468 Phase 2, Phase 3 Dexamethasone
31 Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination Unknown status NCT01795599 Phase 3 Mifegyne ®;Gymiso®
32 Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension Unknown status NCT02801617 Phase 3 PRO-067;GAAP Ofteno®
33 Assessment of Fluticasone Propionate on Ocular Allergy Symptoms Completed NCT01817790 Phase 3 Fluticasone propionate;Placebo
34 Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy Completed NCT01353079 Phase 3
35 Immediate Office Probing vs Deferred Facility Probing for Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old Completed NCT00780741 Phase 3
36 Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED) Completed NCT00783198 Phase 2, Phase 3
37 Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) Completed NCT00770315 Phase 2, Phase 3
38 Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis Completed NCT00884585 Phase 3 Cyclosporine Vehicle;Cyclosporine 0.010%
39 Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. Completed NCT00769886 Phase 3 Ketotifen/naphazoline;Ketotifen;Naphazoline;Vehicle
40 Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis. Completed NCT00770133 Phase 3 Ketotifen/naphazoline;Naphazoline;Ketotifen;Vehicle
41 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis Completed NCT00445874 Phase 3 Ketotifen with a Contact Lens (no generic name)
42 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis Completed NCT00432757 Phase 3 Ketotifen with a Contact Lens (generic name not yet established)
43 Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis Completed NCT00423007 Phase 3 Bromfenac;Placebo
44 A Trial of Topical Dexamethasone Versus Artificial Tears for Treatment of Viral Conjunctivitis Completed NCT01481519 Phase 3 dexamethasone 0.1%/povidone-iodine 0.4%;Artificial Tears
45 Trial of STAHIST in Seasonal Allergic Rhinitis Completed NCT01293201 Phase 3 STAHIST;Placebo
46 Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies Completed NCT00599872 Phase 3
47 Phase III Cat-PAD Follow-on Study Completed NCT02040844 Phase 3 Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762];Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762];Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]
48 Trial of CF101 to Treat Patients With Dry Eye Disease Completed NCT01235234 Phase 3 CF101
49 Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis Completed NCT00244543 Phase 3 R89674 (generic name not yet established)
50 Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis Completed NCT00241319 Phase 3 R89674 (generic name not yet established)

Search NIH Clinical Center for Excessive Tearing

Cochrane evidence based reviews: lacrimal apparatus diseases

Genetic Tests for Excessive Tearing

Anatomical Context for Excessive Tearing

MalaCards organs/tissues related to Excessive Tearing:

41
Eye, Breast, Bone, Thyroid, B Cells, Salivary Gland

Publications for Excessive Tearing

Articles related to Excessive Tearing:

# Title Authors Year
1
Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. ( 23650421 )
2013
2
Epiphora and canalicular stenosis associated with adjuvant docetaxel in early breast cancer: is excessive tearing clinically important? ( 23650413 )
2013
3
Index of Suspicion. Case 1: Irritability and signs of peritonitis in a neonate. Case 2: Red eye, excessive tearing, photophobia, irritability, and splenomegaly in an infant. Case 3: 2-year-old girl who has cough, right pulmonary abnormalities. ( 22383516 )
2012
4
Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. ( 16645230 )
2006
5
Management of excessive tearing as a side effect of docetaxel. ( 15748466 )
2005
6
Excessive tearing in infancy and early childhood. The role and treatment of congenital nasolacrimal duct obstruction. ( 10865874 )
2000

Variations for Excessive Tearing

Expression for Excessive Tearing

Search GEO for disease gene expression data for Excessive Tearing.

Pathways for Excessive Tearing

Pathways related to Excessive Tearing according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 FGF10 GNAT2 LTBP2

GO Terms for Excessive Tearing

Cellular components related to Excessive Tearing according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 8.8 FGF10 LTBP2 MYOC

Biological processes related to Excessive Tearing according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood vessel morphogenesis GO:0048514 8.62 CYP1B1 FGF10

Sources for Excessive Tearing

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....